Search research articles
Contact Us
Filters
Showing results (41-50 of 79) with videos related to
Page
of 8
Sort By:
European Urology Focus
|
November 15, 2022
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review
Anne Neuenschwander, Chiara Lonati, Luca Antonelli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 5, 2024
Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue
Bettina Sobottka, Viola Vetter, Amir Banaei-Esfahani, et al.
Urologic Oncology
|
September 11, 2024
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels
Christian D Fankhauser, Marian S Wettstein, Ailsa J Christiansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
Richard Cathomas, Dirk Klingbiel, Brandon Bernard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2007
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group
Anja Lorch, Christian Kollmannsberger, Joerg Thomas Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database
Anja Lorch, Caroline Bascoul-Mollevi, Andrew Kramar, et al.
Frontiers in Oncology
|
December 26, 2022
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
Ailsa J Christiansen, João Lobo, Christian D Fankhauser, et al.
British Journal of Cancer
|
December 16, 2021
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours
Christian D Fankhauser, Ailsa J Christiansen, Christian Rothermundt, et al.
International Journal of Cancer
|
May 31, 2023
Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study
Max J Rieger, Xenia Schenkel, Ivona Dedic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy
, Anja Lorch, Jörg Beyer, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 79) with videos related to
Sort By:
Page
of 8
European Urology Focus
|
November 15, 2022
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review
Anne Neuenschwander, Chiara Lonati, Luca Antonelli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 5, 2024
Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue
Bettina Sobottka, Viola Vetter, Amir Banaei-Esfahani, et al.
Urologic Oncology
|
September 11, 2024
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels
Christian D Fankhauser, Marian S Wettstein, Ailsa J Christiansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2018
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry
Richard Cathomas, Dirk Klingbiel, Brandon Bernard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2007
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group
Anja Lorch, Christian Kollmannsberger, Joerg Thomas Hartmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database
Anja Lorch, Caroline Bascoul-Mollevi, Andrew Kramar, et al.
Frontiers in Oncology
|
December 26, 2022
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
Ailsa J Christiansen, João Lobo, Christian D Fankhauser, et al.
British Journal of Cancer
|
December 16, 2021
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours
Christian D Fankhauser, Ailsa J Christiansen, Christian Rothermundt, et al.
International Journal of Cancer
|
May 31, 2023
Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study
Max J Rieger, Xenia Schenkel, Ivona Dedic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy
, Anja Lorch, Jörg Beyer, et al.
Page
of 8